SPRY2 and neoplasm: Re-establishing feedback inhibition in Sprouty-low tumours may therefore be an effective strategy for combinatorial therapy with trastuzumab, and raises the possibility that in some HER2 overexpressing tumours, high expression of Spry2 may be a marker of response to trastuzumab.